Blood-brain barrier models: Rationale for selection

Hanafy, Amira Sayed; Dietrich, Dirk; Fricker, Gert; Lamprecht, Alf

doi:10.1016/j.addr.2021.113859

Cited by 33 publications

(16 citation statements)

References 245 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ability of the plant products to cross the BBB can be tested with various in vitro and in vivo BBB models [ 470 ]. However, major challenges remain with current BBB models, which have limited ability to recapitulate barrier dysfunction and plaque deposition [ 471 ].…”

Section: Resultsmentioning

confidence: 99%

Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimer’s disease

Tyler

2022

Nat. Prod. Bioprospect.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is progressive and ultimately fatal, with current drugs failing to reverse and cure it. This study aimed to find plant species which may provide therapeutic bioactivities targeted to causal agents proposed to be driving AD. A novel toolkit methodology was employed, whereby clinical symptoms were translated into categories recognized in ethnomedicine. These categories were applied to find plant species with therapeutic effects, mined from ethnomedical surveys. Survey locations were mapped to assess how this data is at risk. Bioactivities were found of therapeutic relevance to 15 hypothesised causal bases for AD. 107 species with an ethnological report of memory improvement demonstrated therapeutic activity for all these 15 causal bases. The majority of the surveys were found to reside within biodiversity hotspots (centres of high biodiversity under threat), with loss of traditional knowledge the most common threat. Our findings suggest that the documented plants provide a large resource of AD therapeutic potential. In demonstrating bioactivities targeted to these causal bases, such plants may have the capacity to reduce or reverse AD, with promise as drug leads to target multiple AD hallmarks. However, there is a need to preserve ethnomedical knowledge, and the habitats on which this knowledge depends. Graphical Abstract

show abstract

Section: Resultsmentioning

confidence: 99%

Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimer’s disease

Tyler

2022

Nat. Prod. Bioprospect.

View full text Add to dashboard Cite

show abstract

“…It has been reported that most drug concentrations in the blood of rats can reach a peak within 1–2 h after taking TCM, which is consistent with the physiological characteristics of drug absorption into the blood of rats, and the plasma obtained at this time is drug-containing plasma. ( Mehta et al, 2015 ; Hanafy et al, 2021 ). Therefore, in this study, the plasma samples at 1 h after administration were used for the analysis of components in plasma.…”

Section: Resultsmentioning

confidence: 99%

An Integrated Strategy to Identify and Quantify the Quality Markers of Xinkeshu Tablets Based on Spectrum-Effect Relationship, Network Pharmacology, Plasma Pharmacochemistry, and Pharmacodynamics of Zebrafish

et al. 2022

View full text Add to dashboard Cite

Xinkeshu tablets (XKST), a traditional Chinese patent medicine (CPM), have served in the clinical treatment of cardiovascular diseases (CVDs) for decades. However, its pharmacodyamic material basis was still unclear, and the holistic quality control has not been well established due to the lack of systematic research on the quality markers. In this experiment, the heart rate recovery rate of a zebrafish larva was used to evaluate the traditional pharmacological effect of XKST i.e., antiarrhythmic effect. The HPLC fingerprints of 16 batches of XKST samples were obtained, and antiarrhythmic components of XKST were identified by establishing the spectrum-effect relationship between HPLC fingerprints and heart rate recovery rate of zebrafish larva with orthogonal signal correction and partial least squares regression (OSC–PLSR) analysis. The anticardiovascular disease components of XKST were identified by mapping the targets related to CVDs in network pharmacology. The compounds of XKST absorbed and exposed in vivo were identified by ultra-high performance liquid chromatography Q-Exactive high-resolution mass spectrometry (UHPLC-Q-Exactive HRMS). Based on the earlier studies, combined with five principles for identifying quality markers and verified by a zebrafish arrhythmia model, danshensu, salvianolic acid A, salvianolic acid B, daidzein, and puerarin were identified as quality markers of XKST. In total, 16 batches of XKST samples were further quantified with the method established in this study. Our study laid the foundation for the quality control of XKST. The integrated strategy used in the study of XKST could be applied for the identification and quantification of quality markers of other CPMs as well.

show abstract

“…There is growing evidence that ACs are involved in the upregulation of many BBB features, including the tightening of TJs [ 44 , 45 , 46 ]. Figure 2 gives an overview of the cellular constituents of the blood brain barrier [ 47 ].…”

Section: Blood–brain Barrier (Bbb)mentioning

confidence: 99%

“…Although establishing a BBB model is a challenging task, a successful model should meet specific requirements and parameters to guarantee data consistency, reproducibility, and precise correspondence with the complex nature of the BBB. Any established model of the BBB should accurately mimic the BBB architecture, including ECs, Acs, PCs with luminal and abluminal sides, and articulate TJs and adherence junctions (AJs) in the endothelium [ 47 , 73 ]. The reliability of the model will also depend on its ability to proliferate and differentiate ECs while including glia and apical membrane.…”

Section: Blood–brain Barrier (Bbb)mentioning

confidence: 99%

Advances in Hydrogel-Based Microfluidic Blood–Brain-Barrier Models in Oncology Research

et al. 2022

View full text Add to dashboard Cite

The intrinsic architecture and complexity of the brain restricts the capacity of therapeutic molecules to reach their potential targets, thereby limiting therapeutic possibilities concerning neurological ailments and brain malignancy. As conventional models fail to recapitulate the complexity of the brain, progress in the field of microfluidics has facilitated the development of advanced in vitro platforms that could imitate the in vivo microenvironments and pathological features of the blood–brain barrier (BBB). It is highly desirous that developed in vitro BBB-on-chip models serve as a platform to investigate cancer metastasis of the brain along with the possibility of efficiently screening chemotherapeutic agents against brain malignancies. In order to improve the proficiency of BBB-on-chip models, hydrogels have been widely explored due to their unique physical and chemical properties, which mimic the three-dimensional (3D) micro architecture of tissues. Hydrogel-based BBB-on-chip models serves as a stage which is conducive for cell growth and allows the exchange of gases and nutrients and the removal of metabolic wastes between cells and the cell/extra cellular matrix (ECM) interface. Here, we present recent advancements in BBB-on-chip models targeting brain malignancies and examine the utility of hydrogel-based BBB models that could further strengthen the future application of microfluidic devices in oncology research.

show abstract

Blood-brain barrier models: Rationale for selection

Cited by 33 publications

References 245 publications

Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimer’s disease

Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimer’s disease

An Integrated Strategy to Identify and Quantify the Quality Markers of Xinkeshu Tablets Based on Spectrum-Effect Relationship, Network Pharmacology, Plasma Pharmacochemistry, and Pharmacodynamics of Zebrafish

Advances in Hydrogel-Based Microfluidic Blood–Brain-Barrier Models in Oncology Research

Contact Info

Product

Resources

About